Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
selurampanel
- Development stage
- Phase 2
- Lead developer
- Novartis
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Selurampanel is an orally active, small molecule drug that acts as a competitive antagonist at the AMPA and kainate subtypes of ionotropic glutamate receptors. It is structurally related to the quinoxalinedione series and competes with glutamate for binding at these receptor sites. Selurampanel has been primarily developed for epilepsy, with additional investigation in migraine and other indications such as adrenocortical adenoma and endometrial stromal sarcoma. The drug demonstrates reasonable blood-brain barrier penetration and was under clinical development by Novartis, reaching up to phase 2 trials for epilepsy. Its mechanism of action involves blocking excitatory neurotransmission mediated by AMPA/kainate receptors, which may help control seizures in patients with epilepsy[1][3][4][5][8].
- Other names
- selurampanel
02
Targets
AMPAR (AMPA receptor)Kainate-type ionotropic glutamate receptor
Beyond the preview
Go deeper on selurampanel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on selurampanel.